Ralliant (NYSE:RAL) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Ralliant (NYSE:RAL) from a strong-buy rating to a buy rating in a report published on Sunday,Wall Street Zen reports.

Several other research analysts also recently weighed in on RAL. Evercore started coverage on Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target for the company. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Citigroup upped their price objective on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. Morgan Stanley increased their target price on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Trading Down 1.1%

NYSE:RAL opened at $61.06 on Friday. Ralliant has a 12 month low of $37.27 and a 12 month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The firm’s 50 day moving average is $68.12 and its 200 day moving average is $56.79. The stock has a market capitalization of $6.76 billion, a PE ratio of -5.63, a price-to-earnings-growth ratio of 2.29 and a beta of 1.54.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Sell-side analysts expect that Ralliant will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s payout ratio is -1.84%.

Insider Buying and Selling at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 6,062 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. This trade represents a 16.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. This represents a 4.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ralliant

Hedge funds and other institutional investors have recently modified their holdings of the stock. Danske Bank A S purchased a new stake in shares of Ralliant in the fourth quarter worth about $25,000. Dunhill Financial LLC bought a new position in shares of Ralliant in the 2nd quarter worth $25,000. Allworth Financial LP raised its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter valued at $26,000. Finally, BOKF NA purchased a new position in Ralliant in the third quarter worth $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.